Egloff Heidi, Jatoi Aminah
a Department of Medicine , Mayo Clinic , Rochester , Minnesota , USA.
b Department of Oncology , Mayo Clinic , Rochester , Minnesota , USA.
Cancer Invest. 2016 Nov 25;34(10):531-535. doi: 10.1080/07357907.2016.1242011. Epub 2016 Oct 28.
Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancer patients at risk for breast cancer susceptibility (BRCA) mutation.
METHODS/RESULTS: Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival.
Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancer patients treated with curative intent.
很少有研究探讨具有乳腺癌易感性（BRCA）突变风险的卵巢癌患者接受潜在治愈性化疗时的毒性。
方法/结果：482例患者中，94例基于家族史有突变风险，23例确诊有突变。基于家族史，住院或急诊就诊次数并未增加，优势比（95%置信区间）分别为0.88（0.52，1.45）（p = 0.62）和0.90（0.49，1.58）（p = 0.71）；确诊有突变时也观察到类似结果。有生存改善的趋势。
对于有治愈意图的卵巢癌患者，担心BRCA突变不应排除给予全剂量化疗。
